{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T04:15:57Z","timestamp":1764648957013,"version":"3.46.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["Z181100006218044","Z211100002121163"],"award-info":[{"award-number":["Z181100006218044","Z211100002121163"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RZG2024-01","RD2024-14"],"award-info":[{"award-number":["RZG2024-01","RD2024-14"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32441099","82230121","82371807","82171773"],"award-info":[{"award-number":["32441099","82230121","82371807","82171773"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.autrev.2025.103913","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T22:11:44Z","timestamp":1755555104000},"page":"103913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid radiographic progression in rheumatoid arthritis: Definition, prediction and treatment"],"prefix":"10.1016","volume":"24","author":[{"given":"Bo","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanshu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanlei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103913_bb0005","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Js","year":"2016","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.autrev.2025.103913_bb0010","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/kez450","article-title":"A simplified radiographic score effectively predicts radiographic progression of early arthritis in a large nationwide French cohort","volume":"59","author":"Carvajal Alegria","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103913_bb0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/03009742.2021.1917161","article-title":"Early radiological progression remains associated with long-term joint damage in real-world rheumatoid arthritis patients treated to the target of remission","volume":"51","author":"Versteeg","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0020","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1136\/annrheumdis-2011-201212","article-title":"Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up","volume":"71","author":"Van Den Broek","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/rheumatology\/keg036","article-title":"The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials","volume":"42","author":"Jones","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103913_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"723\u20139","key":"10.1016\/j.autrev.2025.103913_bb0035","first-page":"vi","article-title":"Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations","volume":"35","author":"Yazici","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"first-page":"215","year":"2009","series-title":"Total sharp score (TSS). Dictionary of rheumatology","key":"10.1016\/j.autrev.2025.103913_bb0040"},{"key":"10.1016\/j.autrev.2025.103913_bb0045","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/ard.2009.121160","article-title":"A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study","volume":"69","author":"Visser","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0050","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103913_bb0055","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/rheumatology\/kez542","article-title":"An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases","volume":"59","author":"Vanier","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103913_bb0060","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12891-021-04192-x","article-title":"Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients","volume":"22","author":"V\u00e9gh","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"10.1016\/j.autrev.2025.103913_bb0065","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3899\/jrheum.131468","article-title":"Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment","volume":"41","author":"Kaneko","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0070","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/ard.2010.135319","article-title":"Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort","volume":"70","author":"Durnez","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0075","doi-asserted-by":"crossref","first-page":"R249","DOI":"10.1186\/ar4092","article-title":"Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort","volume":"14","author":"Fautrel","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103913_bb0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13075-018-1575-2","article-title":"Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis","volume":"20","author":"Rydell","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103913_bb0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/rheumatology\/keg062","article-title":"How to interpret radiological progression in randomized clinical trials?","volume":"42","author":"Landew\u00e9","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103913_bb0090","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/art.10190","article-title":"Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the sharp\/van der heijde and larsen\/Scott scoring methods by clinical experts and comparison with the smallest detectable difference","volume":"46","author":"Bruynesteyn","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0095","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3899\/jrheum.150988","article-title":"Magnetic resonance imaging bone edema at enrollment predicts rapid radiographic progression in patients with early RA: results from the Nagasaki University early arthritis cohort","volume":"43","author":"Nakashima","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/acr2.11123","article-title":"Modified disease activity score at 3 months is a significant predictor for rapid radiographic progression at 12 months compared with other measures in patients with rheumatoid arthritis","volume":"2","author":"Movahedi","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0105","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1172\/JCI117753","article-title":"Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism","volume":"95","author":"M\u00e5nsson","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103913_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3892\/br.2021.1407","article-title":"A genome-wide association study identifying the SNPs predictive of rapid joint destruction in patients with rheumatoid arthritis","volume":"14","author":"Hayashi","year":"2021","journal-title":"Biomed Rep"},{"key":"10.1016\/j.autrev.2025.103913_bb0115","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.21739","article-title":"The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis","volume":"54","author":"van der Helm-van Mil","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaut.2008.11.004","article-title":"Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis","volume":"32","author":"Rojas-Villarraga","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103913_bb0125","article-title":"Inflammatory cytokines in general and central obesity and modulating effects of physical activity","volume":"10","author":"Schmidt","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2025.103913_bb0130","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2011-200975","article-title":"Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0135","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/rheumatology\/40.5.544","article-title":"Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and in\u00afammation in early rheumatoid arthritis. A prospective 5-year study","volume":"40","author":"Roux-Lombard","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103913_bb0140","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/acr.23579","article-title":"Obesity, weight loss, and progression of disability in rheumatoid arthritis","volume":"70","author":"Baker","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103913_bb0145","first-page":"2350","article-title":"Relation between body mass index and radiological progression in patients with rheumatoid arthritis","volume":"30","author":"Kaufmann","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0150","first-page":"161","article-title":"Benefit of Filgotinib, a JAK1 preferential inhibitor, in rheumatoid arthritis patients with previous rapid radiographic progression: post hoc analysis of two trials","volume":"10","author":"Tanaka","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2025.103913_bb0155","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/ard.2007.078832","article-title":"A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis","volume":"67","author":"van der Helm-van Mil","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0160","first-page":"3","article-title":"Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial","author":"Levitsky","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103913_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004227","article-title":"Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study","volume":"10","author":"Dubovyk","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103913_bb0170","first-page":"317","article-title":"Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine","volume":"115","author":"Bray","year":"2016","journal-title":"WMJ: Off Publ State Med Soc Wis"},{"key":"10.1016\/j.autrev.2025.103913_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135327","article-title":"Heterogeneous disease trajectories explain variable radiographic, function and quality of life outcomes in the Canadian early arthritis cohort (CATCH)","volume":"10","author":"Barnabe","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2025.103913_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002817","article-title":"Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis","volume":"9","author":"Motta","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103913_bb0185","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","article-title":"The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide","volume":"43","author":"Schellekens","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0195","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/ard.2006.068247","article-title":"High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study","volume":"67","author":"Syversen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0200","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s10067-019-04554-w","article-title":"Association of cumulative anti-cyclic citrullinated protein antibodies with radiographic progression in patients with rheumatoid arthritis","volume":"38","author":"Joo","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93688","article-title":"Anti-citrullinated protein antibodies cause arthritis by cross-reactivity to joint cartilage","volume":"2","author":"Ge","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2025.103913_bb0210","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1084\/jem.20160792","article-title":"Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor","volume":"213","author":"Tan","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2025.103913_bb0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/tcmj.tcmj_116_18","article-title":"The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis","volume":"31","author":"Yu","year":"2019","journal-title":"Tzu Chi Med J"},{"key":"10.1016\/j.autrev.2025.103913_bb0220","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/1529-0131(200006)43:6<1371::AID-ANR22>3.0.CO;2-R","article-title":"Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: an early marker of progressive erosive disease","volume":"43","author":"Mustila","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0225","first-page":"1054","article-title":"Antineutrophil cytoplasmic antibodies in rheumatoid arthritis","volume":"36","author":"Mulder","year":"1993","journal-title":"Character Clin Correlat Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0230","first-page":"481","article-title":"Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films","volume":"18","author":"Larsen","year":"1977","journal-title":"Acta Radiol"},{"key":"10.1016\/j.autrev.2025.103913_bb0235","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrrheum.2015.171","article-title":"Cytokines in rheumatoid arthritis - shaping the immunological landscape","volume":"12","author":"McInnes","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41927-017-0001-8","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets","volume":"1","author":"Alunno","year":"2017","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0245","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/ard.2009.121764","article-title":"Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis","volume":"69","author":"Van Tuyl","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0250","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1002\/art.22923","article-title":"Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers","volume":"56","author":"Young-Min","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0255","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3899\/jrheum.080180","article-title":"Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression","volume":"36","author":"Syversen","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0260","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.3390\/biomedicines11112998","article-title":"Adipokines in rheumatoid arthritis: emerging biomarkers and therapeutic targets","volume":"11","author":"Bilski","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2025.103913_bb0265","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/ncprheum0674","article-title":"Adipokines as emerging mediators of immune response and inflammation","volume":"3","author":"Lago","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0270","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/cells10020216","article-title":"Adipokines and autoimmunity in inflammatory arthritis","volume":"10","author":"Neumann","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2025.103913_bb0275","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/acr.24790","article-title":"Adipocytokines and associations with abnormal body composition in rheumatoid arthritis","volume":"75","author":"Baker","year":"2023","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103913_bb0280","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00393-016-0050-1","article-title":"Circulating leptin level in rheumatoid arthritis and its correlation with disease activity: a meta-analysis","volume":"75","author":"Lee","year":"2016","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0285","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/1756-185X.13038","article-title":"Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis","volume":"21","author":"Lee","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0290","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1136\/ard.2011.150813","article-title":"Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis","volume":"70","author":"Giles","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0295","doi-asserted-by":"crossref","DOI":"10.1186\/ar4404","article-title":"Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort","volume":"15","author":"Meyer","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103913_bb0300","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/art.30449","article-title":"Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis","volume":"63","author":"Klein-Wieringa","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0305","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/annrheumdis-2013-204986","article-title":"Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial","volume":"74","author":"Hambardzumyan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0310","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/rheumatology\/kem288","article-title":"Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis","volume":"47","author":"Verschueren","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103913_bb0315","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1093\/rheumatology\/keaf149","article-title":"Do MRI-detected erosions in the RA-risk phase of arthralgia reflect current or imminent radiographic erosions? A large longitudinal imaging study","volume":"64","author":"Dumoulin","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103913_bb0320","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2024-0560","article-title":"Changes at presentation in patients with early rheumatoid arthritis: a 24-year study of the early undifferentiated polyarthritis (EUPA) cohort","author":"Carrier","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0325","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1002\/art.23364","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"58","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0330","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jbspin.2007.06.001","article-title":"The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients","volume":"74","author":"Combe","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2025.103913_bb0335","first-page":"74","article-title":"Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial","author":"S S, H R, P G, I P, S E, K A","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000245","article-title":"Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data","volume":"2","author":"Granger","year":"2016","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.autrev.2025.103913_bb0345","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/acr.21870","article-title":"The performance of matrix-based risk models for rapid radiographic progression in BRASS, a cohort of patients with established rheumatoid arthritis","volume":"65","author":"Lillegraven","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103913_bb0350","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2012-eular.2526","article-title":"Performance of rapid radiographic progression prediction matrices in the early rheumatoid arthritis patients of the espoir cohort","volume":"71","author":"Fautrel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0355","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.semarthrit.2013.09.004","article-title":"The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA","volume":"43","author":"De Cock","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0360","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0365","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","article-title":"Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0370","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/annrheumdis-2016-210561","article-title":"Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0375","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0380","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/annrheumdis-2013-204762","article-title":"The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy","volume":"73","author":"Conaghan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0385","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2025.103913_bb0390","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","article-title":"Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial","volume":"71","author":"Stohl","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0395","article-title":"Abstract supplement ACR convergence 2023","volume":"75","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0400","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0405","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.autrev.2025.103913_bb0410","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0415","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0420","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0425","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol (Hob NJ)"},{"key":"10.1016\/j.autrev.2025.103913_bb0430","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s40744-023-00590-w","article-title":"Prevention of radiographic progression in higher-risk patients with rheumatoid arthritis using Filgotinib in phase III studies: narrative review of post hoc analyses","volume":"10","author":"Tanaka","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2025.103913_bb0435","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s10067-018-4221-0","article-title":"Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study","volume":"37","author":"van der Heijde","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103913_bb0440","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103913_bb0445","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0450","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four\u2013month, phase III study","volume":"71","author":"Van Der Heijde","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0455","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0460","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ard.2025.03.002","volume":"84","author":"Hetland","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103913_bb0465","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/art.21421","article-title":"Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial","volume":"52","author":"Wassenberg","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103913_bb0470","article-title":"Dual biologic therapy in patients with rheumatoid arthritis and psoriatic arthritis","volume":"14","author":"Department of Rheumatology, Tel Aviv Sourasky Medical Center","year":"2023","journal-title":"Rambam Maimonides Med J"},{"key":"10.1016\/j.autrev.2025.103913_bb0475","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate: a randomized, double-blind study","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol (Hob NJ)"},{"key":"10.1016\/j.autrev.2025.103913_bb0480","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2018.12.003","article-title":"Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"49","author":"Boleto","year":"2019","journal-title":"Semin Arthritis Rheum"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T04:13:51Z","timestamp":1764648831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":96,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1568997225001740"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103913","relation":{},"ISSN":["1568-9972"],"issn-type":[{"type":"print","value":"1568-9972"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid radiographic progression in rheumatoid arthritis: Definition, prediction and treatment","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103913"}}